Clinical trials: Bacterial Urinary Tract Infection
Urinary Tract Infections, Bacterial Pneumonia
Ertapenem Study in Pediatric Patients Who Have Urinary Tract Infections, Skin Infections or Community-acquired Pneumonia (0826-036)
This study will investigate the safety and efficacy of ertapenem versus ceftriaxone in pediatric patients with urinary tract infections, skin infections, or community-acquired pneumonia.
- Conditions
- Urinary Tract Infections, Bacterial Pneumonia, Soft Tissue Infections
- Trial name
- NCT00451386
- Testing
- MK0826, ertapenem sodium /Duration of Treatment: 14 Days, Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days
- Volunteers
- 400 people
- Sponsor
- Merck Sharp & Dohme LLC
Complicated Urinary Tract Infection, Acute Pyelonephritis
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
This study is a multi-center, randomized, single-blind, parallel-group study to assess the efficacy and safety, when nacubactam is coadministered with cefepime or aztreonam, compared with best available therapy (BAT), in the…
- Conditions
- Complicated Urinary Tract Infection, Acute Pyelonephritis, Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia
- Trial name
- Integral-2 (NCT05905055)
- Testing
- co-administration of cefepime and nacubactam, co-administration of aztreonam and nacubactam, BAT
- Where
- 54 sites in China, Croatia and 12 more
- Volunteers
- 126 people
- Sponsor
- Meiji Seika Pharma Co., Ltd.
Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
This was a Phase 3 study containing a randomized open-label superiority cohort (Cohort 1) comparing the efficacy and safety of plazomicin with colistin when combined with a second antibiotic (either meropenem or tigecycline) in…
- Conditions
- Bloodstream Infections (BSI) Due to CRE, Hospital-Acquired Bacterial Pneumonia (HABP) Due to CRE, Ventilator-Associated Bacterial Pneumonia (VABP) Due to CRE, Complicated Urinary Tract Infection (cUTI) Due to CRE
- Trial name
- CARE (NCT01970371)
- Testing
- plazomicin, colistin, meropenem
- Volunteers
- 69 people
- Sponsor
- Achaogen, Inc.
Urinary Tract Infection, Acute Pyelonephritis
Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults
This is an open-label, randomized, multi-center, interventional, active-controlled Phase 4 study to evaluate the efficacy and safety of CAZ-AVI versus BAT in the treatment of infected participants with selected infection types…
- Conditions
- Urinary Tract Infection, Acute Pyelonephritis, Hospital Acquired Pneumonia, Ventilator-associated Pneumonia
- Trial name
- NCT04882085
- Testing
- Zavicefta, Ceftazidime-Avibactam, Best Available Treatment
- Where
- 37 sites in China
- Volunteers
- 60 people
- Sponsor
- Pfizer
Urinary Tract Infections (UTIs)
Sensitivity of Antibiotics for Urinary Tract Infections Patients Attending Family Physicians
This study is aiming to evaluate the sensitivity of uropathogens isolated in patients with community acquired UTI with Enoxacin in comparison to other antimicrobials.
- Trial name
- NCT02305342
- Where
- Pakistan
- Volunteers
- 350 people
- Sponsor
- Abbott
Pneumonia, Bacterial, Nosocomial Infection
A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections
The purpose of this study is to assess the safety and effectiveness of doripenem treatment among Filipino patients with nosocomial pneumonia, complicated intra-abdominal infections, and complicated urinary tract infection.
- Conditions
- Pneumonia, Bacterial, Nosocomial Infection, Intraabdominal Infections, Urinary Tract Infection
- Trial name
- NCT01763008
- Testing
- No intervention
- Where
- 4 sites in Philippines
- Volunteers
- 170 people
- Sponsor
- Janssen Pharmaceutica
Infection, Cross Infection
A Safety and Efficacy Study of Doripenem in Participants With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Urinary Tract Infections
The purpose of this study is to assess the safety and efficacy of doripenem in participants with nosocomial pneumonia (inflammation of the lungs in which the lungs become heavy; pneumonia occurring at least 48 hours after…
- Conditions
- Infection, Cross Infection, Bacterial Infections, Pneumonia, Ventilator-Associated
- Trial name
- NCT00965848
- Testing
- Doripenem
- Where
- 8 sites in Thailand
- Volunteers
- 270 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP)
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
The study will evaluate the efficacy and safety of Meropenem and Pralurbactam versus Best Available Therapy in the treatment of Carbapenem-Resistant Enterobacteriaceae Infections.
- Conditions
- Hospital-acquired Bacterial Pneumonia (HABP), Ventilator-associated Bacterial Pneumonia (VABP), Complicated Intra-abdominal Infection (cIAI), Complicated Urinary Tract Infection (cUTI)
- Trial name
- NCT07089186
- Testing
- Meropenem and Pralurbactam, Best Available Therapy (e.g., colistin, meropenem, tegecycline, amikacinceftezidime-avibatam)
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Bacterial Infections
Evaluation of the Artificial Intelligence-based Prescription Support Software iAST® for the Choice of Empirical and Semi-targeted Antibiotic Treatment
Inadequate treatment of infections frequently leads to complications that cause new visits to the doctor, lengthen hospital stays and can lead to sepsis, even causing the death of affected patients.
- Trial name
- EVIAST (NCT06174519)
- Testing
- Medical device simulation
- Where
- Spain
- Volunteers
- 325 people
- Sponsor
- Pragmatech AI Solutions
Respiratory Tract Infections, Urinary Tract Infections in Children
PHase IV Clinical Trial of Ceftriaxone Sodium and Sulbactam Sodium for Injection (CRO-SBT)
To evaluate the safety and efficacy of treatment of children with acute bacterial infection disease with Ceftriaxone Sodium and Sulbactam Sodium for Injection in the condition of widely used, and provide the basis of adjusting…
- Trial name
- CRO-SBT (NCT04066621)
- Testing
- Ceftriaxone Sodium and Sulbactam Sodium for Injection
- Volunteers
- 30 people
- Sponsor
- Xiangbei Welman Pharmaceutical Co., Ltd
Bacterial Infections, Urinary Tract Infections
Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers
This Phase I study is a randomized, double-blind, placebo-controlled, dose-escalation trial conducted at a single center. It consists of two parts: Part 1 (SAD): Evaluates the safety, tolerability, and pharmacokinetics (PK) of…
- Conditions
- Bacterial Infections, Urinary Tract Infections, Intra-Abdominal Infections, Respiratory Tract Infections
- Trial name
- NCT07207291
- Testing
- JKN2501
- Where
- China
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Joincare Pharmaceutical Group Industry Co., Ltd
Urinary Tract Infection Bacterial
Bacteriophage Therapy in Patients With Urinary Tract Infections
This is a phase I/II trial designed to evaluate bacteriophage therapy in patients with urinary tract infections.
- Trial name
- NCT04287478
- Testing
- Bacteriophage Therapy
- Where
- 8 sites in United States
- Volunteers
- 1 people
- Sponsor
- Adaptive Phage Therapeutics, Inc.
Urinary Tract Infections, Pyelonephritis
Safety, Tolerability, and Efficacy of MK-7655 (Relebactam) + Imipenem/Cilastatin Versus Imipenem/Cilastatin Alone for Treating Complicated Urinary Tract Infection (cUTI) (MK-7655-003)
The purpose of this study is to evaluate the efficacy, safety and tolerability of adding 125 mg or 250 mg doses of MK-7655 (relebactam) to imipenem/cilastatin in adults 18 years or older with complicated urinary tract infection…
- Trial name
- NCT01505634
- Testing
- Relebactam 250 mg, Relebactam 125 mg, imipenem/cilastatin 500 mg
- Volunteers
- 302 people
- Sponsor
- Merck Sharp & Dohme LLC
Urinary Tract Infections, Chronic Urinary Tract Infection
Expanded Access Program Using Uromune for Patients With Recurrent Urinary Tract Infections (rUTI)
An Expanded Access Program for UROMUNE® for patients suffering from recurrent/chronic urinary tract infections of diverse etiology.
- Conditions
- Urinary Tract Infections, Chronic Urinary Tract Infection, Recurrent Urinary Tract Infection, Urinary Tract Infection Bacterial
- Trial name
- NCT04173013
- Testing
- Uromune
- Where
- 15 sites in Belgium, Czechia and 13 more
- Sponsor
- Impatients N.V. trading as myTomorrows
Urinary Tract Infections, Bacterial Infections
A Study of the Safety and Effectiveness of Levofloxacin Compared With Lomefloxacin in the Treatment of Complicated Urinary Tract Infections
The purpose of the study is to compare the safety and effectiveness of oral levofloxacin (an antibiotic) with that of oral lomefloxacin in the treatment of complicated urinary tract infections in adults.
- Conditions
- Urinary Tract Infections, Bacterial Infections, Bacteriuria, Urologic Diseases
- Trial name
- NCT00258102
- Testing
- Levofloxacin
- Volunteers
- 603 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
COVID-19, Infectious Disease
Continuous Temperature Telemonitoring of Patients With COVID-19 and Other Infectious Diseases in Hospital at Home Using Viture
The aim of this cohort study is to validate Viture®, a continuous temperature telemonitoring system, evaluating the level of agreement with a standard commercially available digital axillary thermometer.
- Conditions
- COVID-19, Infectious Disease, Tract Infection, Urinary, Bacteremia
- Trial name
- Viture (NCT05959928)
- Testing
- Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely
- Where
- Spain
- Volunteers
- 208 people
- Sponsor
- Vitio Medical S.L.
Urinary Tract Infections
A Study in Pediatric Participants Aged ≥2 to <12 Years With a Suspected or Confirmed Bacterial Infection or Receiving Prophylaxis Antibiotics
The study will be conducted to evaluate how a single oral dose of Gepotidacin is processed in the body over time along with safety monitoring in hospitalized pediatric participants who are receiving a standard of care treatment…
- Trial name
- NCT07371429
- Testing
- Gepotidacin, SOC
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- GlaxoSmithKline
Cystitis / Pyelonephritis / Cystic Fibrosis / Anthrax
Special Drug Use Investigation of Ciproxan Injection in Pediatrics
The objective in this study is collecting post-marketing information on the safety and efficacy of Ciproxan injection under the routine clinical practice.
- Trial name
- NCT02555059
- Testing
- Cipro (Ciprofloxacin, BAYQ3939)
- Where
- Japan
- Volunteers
- 48 people
- Sponsor
- Bayer
Urinary Tract Infections
Study To Evaluate The Efficacy And Safety Of Ciprofloxacin Extended-Release (Cipro® XR) 1000 mg Tablets Given Once Daily For 7 To 14 Days In The Treatment Of Patients 18 Years Or Older With Complicated Urinary Tract Infections Caused By Pseudomonas Aeruginosa And Other Common Uropathogens
Researchers want to find out if a drug called Cipro® XR (ciprofloxacin extended-release) can help people with a complicated urinary tract infection caused by a kind of bacteria called Pseudomonas aeruginosa.
- Trial name
- NCT00481689
- Testing
- Cipro XR (Ciprofloxacin, BAYQ3939)
- Where
- 35 sites in United States
- Volunteers
- 500 people
- Sponsor
- Bayer
Urinary Tract Infections
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the…
- Trial name
- ELIMINATE (NCT05488340)
- Testing
- LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose
- Where
- 17 sites in United States
- Volunteers
- 318 people
- Sponsor
- Locus Biosciences